IE42766L - Pharmaceutical preparations - Google Patents

Pharmaceutical preparations

Info

Publication number
IE42766L
IE42766L IE760011A IE1176A IE42766L IE 42766 L IE42766 L IE 42766L IE 760011 A IE760011 A IE 760011A IE 1176 A IE1176 A IE 1176A IE 42766 L IE42766 L IE 42766L
Authority
IE
Ireland
Prior art keywords
radical
compound
ring
salt
used pharmaceutically
Prior art date
Application number
IE760011A
Other versions
IE42766B1 (en
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of IE42766L publication Critical patent/IE42766L/en
Publication of IE42766B1 publication Critical patent/IE42766B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/618Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/625Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1510370 Compositions for treating coronary heart disease CIBA - GEIGY AG 31 Dec 1975 [6 Jan 1975] 53300/75 Heading A5B Pharmaceutical preparations for the treatment of coronary heart disease contain (1) a beta - receptor blocking compound of the formula:- wherein Ar 1 represents a monocyclic or polycyclic, carbocyclic or heterocyclic radical which contains at least one ring of aromatic character, and which is 'bonded to the oxygen atom via a ring carbon atom, preferably of the ring of aromatic character R 1 denotes an optionally substituted aliphatic, cycloaliphatic or araliphatic hydrocarbon radical and R 2 represents hydrogen or the acyl radical of an organic carboxylic acid, or a compound of the formula wherein R 1 and R 2 have the abovementioned meanings, Ar 2 represents a monocyclic or polycyclic, carbocyclic radical which contains at least one ring of aromatic character, and R 3 denotes hydrogen or lower alkyl, or a salt of such compounds which can be used pharmaceutically, (2) a compound which regulates the thrombocyte function which is acetylsalicylic acid or a salt thereof with a base which can be used pharmaceutically, 2, 6 - bis- [di - (2 - hydroxyethyl) - amino] - 4, 8 - di - piperidino - pyrimido [5, 4 - d] pyrimidine, or an acid addition salt thereof which can be used pharmacetically or a compound of the formula wherein each of the radicals Ph 1 and Ph 2 independently of one another represents a phenyl radical which is optionally substituted by lower alkyl, hydroxyl, lower alkoxy and/or halogen, Alk denotes a lower alkylene radical which separates the sulphur atom from the ring carbon atom by at least 2 carbon atoms, n represents 0, 1 or 2 and Ph 3 represents a phenyl radical which is optionally substituted by lower alkyl, lower alkoxy and/or halogen, or a salt thereof with a base, which can be used pharmacologically, and optionally (3), an alpha - receptor blocking compound which is a hydrogenated ergot alkaloid, or a mixture of such alkaloids or acid addition salts thereof which can be used pharmaceutically, or a N - benzyl - N - halogeno - lower alkylamine, a 2 - tert. - aminomethyl - benzodioxane, a N - substituted dibenzazepine or a methyl - 2 - imidazoline which is substituted in the 2 - position or acid addition salts of such compounds which can be used pharmaceutically. [GB1510370A]
IE11/76A 1975-01-06 1976-01-05 Pharmaceutical preparations for the treatment of coronary heart diseases IE42766B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH7175 1975-01-06

Publications (2)

Publication Number Publication Date
IE42766L true IE42766L (en) 1976-07-06
IE42766B1 IE42766B1 (en) 1980-10-08

Family

ID=4178628

Family Applications (1)

Application Number Title Priority Date Filing Date
IE11/76A IE42766B1 (en) 1975-01-06 1976-01-05 Pharmaceutical preparations for the treatment of coronary heart diseases

Country Status (14)

Country Link
JP (1) JPS5191337A (en)
AU (1) AU499140B2 (en)
BE (1) BE837293A (en)
CA (1) CA1063516A (en)
DE (1) DE2600069A1 (en)
FR (1) FR2296430A1 (en)
GB (1) GB1510370A (en)
HK (1) HK49680A (en)
IE (1) IE42766B1 (en)
IL (1) IL48785A (en)
MY (1) MY8100159A (en)
NL (1) NL7600045A (en)
NZ (1) NZ179623A (en)
ZA (2) ZA7628B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0019006A1 (en) * 1979-05-14 1980-11-26 Ciba-Geigy Ag Pharmaceutical preparations containing a substituted pyrazolidine derivative as active substance, their application and manufacturing process
FR2470599A1 (en) * 1979-12-07 1981-06-12 Panoz Donald IMPROVEMENTS IN PROCESSES FOR THE PREPARATION OF GALENIC SHAPES WITH DELAYED ACTION AND PROGRAMMED RELEASE AND GALENIC FORMS OF MEDICAMENTS THUS OBTAINED
TW284688B (en) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL37700A (en) * 1970-10-02 1975-05-22 Ciba Geigy Ag Pharmaceutical preparations containing an aryloxypropanolamine derivative or an arylethanolamine derivative

Also Published As

Publication number Publication date
CA1063516A (en) 1979-10-02
HK49680A (en) 1980-09-12
ZA7626B (en) 1976-12-29
BE837293A (en) 1976-07-05
AU499140B2 (en) 1979-04-05
NL7600045A (en) 1976-07-08
MY8100159A (en) 1981-12-31
ZA7628B (en) 1976-12-29
FR2296430A1 (en) 1976-07-30
GB1510370A (en) 1978-05-10
DE2600069A1 (en) 1976-07-15
FR2296430B1 (en) 1978-11-10
JPS5191337A (en) 1976-08-10
NZ179623A (en) 1978-03-06
IE42766B1 (en) 1980-10-08
IL48785A0 (en) 1976-03-31
AU1000276A (en) 1977-07-14
IL48785A (en) 1978-08-31

Similar Documents

Publication Publication Date Title
NO164980C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE CARBAPENNAM DERIVATIVES.
NO163855C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE ARYLYCYLOBUTYLALKYLAMINES.
DE3855325D1 (en) Oxothiolanes and derivatives, pharmaceutical preparations containing them and their use as medicines
GB9215844D0 (en) Novel compounds
NO881835D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE BICYCLIC RELATIONS.
IE42766L (en) Pharmaceutical preparations
SE8800171D0 (en) NEW 5-OXY DERIVATIVES OF TETRAHYDROFURAN
JPS57154129A (en) Cardiotonic drug
HUT50176A (en) Process for production of derivatives of heterocyclic lactane and medical compositions containing them as active substance
SE8802997L (en) AMINERY DERIVATIVES AND ITS SALT, PROCEDURES FOR PREPARING THEREOF AND Means against their containing
ES8102122A1 (en) 4-Amino-6,7-dimethoxy quinazoline derivatives, process for their preparation, their use and a pharmaceutical composition.